{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:36:57Z","timestamp":1781231817313,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T00:00:00Z","timestamp":1349136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s40261-012-0008-2","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T23:09:28Z","timestamp":1355958568000},"page":"805-815","source":"Crossref","is-referenced-by-count":18,"title":["Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload"],"prefix":"10.1007","volume":"32","author":[{"given":"Jonathan","family":"Karnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Tolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chandiwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,2]]},"reference":[{"issue":"9","key":"8_CR1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","volume":"331","author":"GM Brittenham","year":"1994","unstructured":"Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567\u201373.","journal-title":"N Engl J Med"},{"issue":"9","key":"8_CR2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","volume":"331","author":"NF Olivieri","year":"1994","unstructured":"Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574\u20138.","journal-title":"N Engl J Med"},{"key":"8_CR3","doi-asserted-by":"crossref","unstructured":"McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009;13(1): iii\u2013iv, ix\u2013xi, 1\u2013121.","DOI":"10.3310\/hta13010"},{"issue":"3","key":"8_CR4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"NF Olivieri","year":"1997","unstructured":"Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739\u201361.","journal-title":"Blood"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","volume":"95","author":"V Gabutti","year":"1996","unstructured":"Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26\u201336.","journal-title":"Acta Haematol"},{"issue":"9","key":"8_CR6","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455\u201362.","journal-title":"Blood"},{"issue":"4","key":"8_CR7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","volume":"118","author":"MD Cappellini","year":"2011","unstructured":"Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5\u00a0years\u2019 follow-up. Blood. 2011;118(4):884\u201393.","journal-title":"Blood"},{"issue":"4","key":"8_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000313447","volume":"123","author":"A Taher","year":"2010","unstructured":"Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220\u20135.","journal-title":"Acta Haematol"},{"issue":"6","key":"8_CR9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1185\/03007990802077442","volume":"24","author":"J Karnon","year":"2008","unstructured":"Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"8_CR10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200725040-00005","volume":"25","author":"TE Delea","year":"2007","unstructured":"Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329\u201342.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"8_CR11","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187\u201393.","journal-title":"Haematologica"},{"issue":"1","key":"8_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4197\/med.17-1.3","volume":"17","author":"SK Al Jaouni","year":"2010","unstructured":"Al Jaouni SK. Survival and Disease Complication of Thalassemia Major: Experience of 14 Years at King Abdulaziz University Hospital, Jeddah, KSA. JKAU Med Sci. 2010;17(1):19\u201328.","journal-title":"JKAU Med Sci"},{"issue":"5","key":"8_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0002-9343(01)00879-8","volume":"111","author":"DT Kremastinos","year":"2001","unstructured":"Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111(5):349\u201354.","journal-title":"Am J Med"},{"issue":"1","key":"8_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2003-09-3167","volume":"104","author":"MJ Cunningham","year":"2004","unstructured":"Cunningham MJ, Macklin EA, Neufeld EJ. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34\u20139.","journal-title":"Blood"},{"issue":"10","key":"8_CR15","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","volume":"47","author":"TE Delea","year":"2007","unstructured":"Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919\u201329.","journal-title":"Transfusion"},{"issue":"22","key":"8_CR16","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood.V114.22.4056.4056","volume":"114","author":"JL Kwiatkowski","year":"2009","unstructured":"Kwiatkowski JL, Kim H-Y, Thompson AA. Chelation choices and iron burden among patients with thalassemia in the 21st century: a report from the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort [Abstract]. Blood. 2009;114(22):4056.","journal-title":"Blood"},{"issue":"6","key":"8_CR17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","volume":"121","author":"R Fischer","year":"2003","unstructured":"Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121(6):938\u201348.","journal-title":"Br J Haematol"},{"key":"8_CR18","unstructured":"British National Formulary 61, British Medical Journal Publishing Group and Pharmaceutical Press, March 2011."},{"key":"8_CR19","unstructured":"Cappellini MD, Taher A, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and tolerability of deferasirox doses >30\u00a0mg\/kg\/day in patients with transfusion-dependent anaemia and iron overload. In: Abstract 0845, European Haematological Association meeting, Copenhagen, Denmark, 12\u201315 June 2008."},{"issue":"8","key":"8_CR20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12325-008-0085-z","volume":"25","author":"KA Payne","year":"2008","unstructured":"Payne KA, Rofail D, Baladi J-F, Viala M, Abetz L, Desrosiers M-P, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25(8):725\u201342.","journal-title":"Adv Ther"},{"issue":"1","key":"8_CR21","first-page":"49","volume":"44","author":"HC Barry","year":"1997","unstructured":"Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44(1):49\u201360.","journal-title":"J Fam Pract"},{"issue":"6","key":"8_CR22","first-page":"545","volume":"44","author":"MH Ebell","year":"1997","unstructured":"Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract. 1997;44(6):545\u201355.","journal-title":"J Fam Pract"},{"key":"8_CR23","unstructured":"Mansel R, on behalf of the ATAC Trialist\u2019s Group. Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in 245 postmenopausal women with early breast cancer: a UK National Health Service perspective. In: 29th European Society for Medical Oncology, Vienna Austria, 29th October\u20132nd November, 2004."},{"key":"8_CR24","doi-asserted-by":"crossref","unstructured":"Curtis L, Netten A. Unit costs of health and social care, 2005. The University of Kent, Personal Social Services Research Unit.","DOI":"10.46692\/9781847421302.006"},{"key":"8_CR25","unstructured":"http:\/\/www.tradingeconomics.com\/united-kingdom\/implied-purchasing-power-parity-ppp-conversion-rate-imf-data.html ."},{"issue":"2","key":"8_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89\u2013102.","journal-title":"Med Decis Making"},{"issue":"8","key":"8_CR27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MPH.0b013e3181ec0f13","volume":"32","author":"MS ElAlfy","year":"2010","unstructured":"ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"8_CR28","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","volume":"92","author":"Y Aydinok","year":"2007","unstructured":"Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599\u2013606.","journal-title":"Haematologica"},{"key":"8_CR29","unstructured":"National Institute for Clinical Excellence, Chronic kidney disease, Costing report Implementing NICE guidance, NICE clinical guideline 73, September 2008, http:\/\/www.nice.org.uk\/nicemedia\/live\/12069\/42209\/42209.PDF ."},{"key":"8_CR30","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: a Systematic Review and Economic Evaluation, 2009, http:\/\/www.nice.org.uk\/nicemedia\/live\/11966\/47853\/47853.pdf ."},{"key":"8_CR31","unstructured":"Thalassaemia International Federation, Guidelines for the Clinical Management of Thalassaemia, 2nd revised edition, November 2008, ISBN: 978-9963-623-70-9."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0008-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0008-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T23:00:05Z","timestamp":1687906805000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0008-2"}},"subtitle":["A UK Perspective"],"short-title":[],"issued":{"date-parts":[[2012,10,2]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0008-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,2]]}}}